Facilitated By

San Antonio Medical Foundation

AN OPEN-LABEL, RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL GROUP, MULTICENTRE, PHASE 3 STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF PA21 COMPARED WITH SEVELAMER CARBONATE FOLLOWED BY A RANDOMIZED COMPARISON OF PA21 MAINTENANCE DOSE VERSUS

UT Health San Antonio

The UT Health San Antonio, with missions of teaching, research and healing, is one of the country’s leading health sciences universities.

Principal Investigator(s)
Qunibi,Wajeh Y
Funded by
VIFOR PHARMA LTD.
Research Start Date
Status
Inactive
Clinical Care
Drug Discovery
Cardiovascular